Todos os estudos
Ativo, mas não recrutandoFASE2INTERVENCIONISTA

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

This study, called NRG Promethean, is for men with a type of prostate cancer that has spread to a few other places in the body, but is still responding to hormone treatments. It compares two approaches: receiving standard radiation therapy by itself, or having radiation therapy along with a new study drug called relugolix. Relugolix works by lowering the amount of testosterone in the body, which can help slow down the growth of prostate cancer. Researchers want to find out if adding relugolix to radiation therapy is better at stopping the cancer from spreading further. The study will also look at side effects and how treatments affect men's quality of life.

Em resumo

Status
Ativo, mas não recrutando
Fase
FASE2
Patrocinador
NRG Oncology
Meta de inscrição
194
Iniciar
20 Abr 2022
Conclusão estimada
01 Feb 2029

Sobre o que é este estudo?

This study is called the NRG Promethean study and it focuses on men who have prostate cancer that has spread to a limited number of other parts of their body, known as 'oligometastatic' prostate cancer. This type of cancer is still sensitive to treatments that reduce male hormones. Currently, the usual treatment for this is radiation therapy, which uses strong energy beams to kill cancer cells.

The study wants to see if adding an oral drug called relugolix to this standard radiation therapy makes the treatment more effective. Relugolix works by lowering the level of testosterone in the body. Since prostate cancer often relies on testosterone to grow, reducing this hormone can help slow or stop the cancer's growth. The main goal is to find out if combining relugolix with radiation therapy can better prevent new cancer spots from appearing or stop the existing ones from growing.

Researchers will compare men who receive just the radiation therapy with those who receive radiation therapy plus relugolix. They will track key things like how long patients go without their cancer noticeably spreading, their quality of life, and any side effects. This will help doctors understand if this new combination treatment could be a better option for men with this specific type of prostate cancer.

Pontos principais

  • This study investigates adding relugolix to standard radiation for specific prostate cancer.
  • Relugolix aims to lower testosterone, which can impact prostate cancer growth.
  • You might receive the active drug or a placebo, alongside radiation.
  • The main goal is to see if the combination better prevents cancer spread.
  • Your quality of life and side effects will be carefully monitored.
  • Participation involves daily medication for six months and regular check-ups.

Quem pode ser elegível?

This study is looking for men aged 18 or older who have been diagnosed with prostate cancer. This cancer must have spread to a few, limited areas in their bones or other soft tissues of the body, but it's still manageable with hormone treatments. You would have had a specific scan (like a PSMA PET scan) recently to show these areas.

To join, you must have already had previous treatments for your prostate cancer that aimed to cure it, such as surgery (prostatectomy) or radiation therapy to the prostate area. You also need to be generally well enough to take part in the study, as assessed by a quick health check.

However, if your cancer has spread very widely, or if you haven't received prior curative-intent treatment for your prostate, this study might not be suitable for you.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Você é um homem com 18 anos ou mais?
  2. Do you have prostate cancer that has spread to 1 to 5 spots in your bones or soft tissues?
  3. Is your prostate cancer still responding to hormone treatments?
  4. Have you previously had surgery or radiation treatment for your prostate cancer?
  5. Are you generally well enough to take part in a study?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to join this study, your involvement would last for about six months of active treatment, with follow-up appointments afterwards. You would be randomly assigned to one of two groups. One group will take a placebo (a dummy pill that looks like the real drug but contains no active medicine) every day for about six months. The other group will take relugolix every day for the same period. Both groups will also receive their usual radiation therapy, which typically lasts for 1 to 3 weeks.

Throughout the study, you'll have various tests and scans, such as bone scans, CT scans, and special PET scans, to monitor your cancer and check how you're responding to treatment. You'll also answer questionnaires about your health and how you're feeling, including questions about your sexual health and general well-being. These assessments will help the study team understand the effects of the treatment and manage any side effects. You'll have regular clinic visits, and the study will oversee your progress and health for an extended period.

Riscos e benefícios potenciais

Participating in this study might offer potential benefits, such as receiving a new treatment (relugolix) that could potentially improve the effectiveness of radiation therapy in preventing your prostate cancer from spreading further. However, it's also possible that you could receive the placebo. There are potential risks, including side effects from relugolix, which works by reducing testosterone, or from the radiation therapy. The study team will closely monitor you for any side effects. You have the right to withdraw from the study at any time, for any reason, without it affecting your future medical care.

Locations (245)

  • Cancer Center at Saint Joseph's
    Código postal verificado
    Phoenix, Estados Unidos
  • Alta Bates Summit Medical Center-Herrick Campus
    Código postal verificado
    Berkeley, Estados Unidos
  • Tower Cancer Research Foundation
    Código postal verificado
    Beverly Hills, Estados Unidos
  • Marin General Hospital
    Código postal verificado
    Greenbrae, United States
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
    Código postal verificado
    Irvine, Estados Unidos
  • Los Angeles General Medical Center
    Código postal verificado
    Los Angeles, Estados Unidos
  • USC / Norris Centro Abrangente de Câncer
    Código postal verificado
    Los Angeles, Estados Unidos
  • Centro Médico Cedars Sinai
    Código postal verificado
    Los Angeles, Estados Unidos
  • Memorial Medical Center
    Código postal verificado
    Modesto, Estados Unidos
  • UC Irvine Health/Chao Family Comprehensive Cancer Center
    Código postal verificado
    Orange, Estados Unidos
  • Sutter Medical Center Sacramento
    Código postal verificado
    Sacramento, Estados Unidos
  • Sutter Pacific Medical Foundation
    Código postal verificado
    Santa Rosa, Estados Unidos

Perguntas frequentes

What is 'oligometastatic' prostate cancer?

This means your prostate cancer has spread to a small, limited number of other spots in your body, rather than very widely.

What is relugolix?

Relugolix is a drug that lowers testosterone levels in the body, which can help slow down the growth of prostate cancer cells.

O que é um 'placebo'?

A placebo is a dummy pill with no active medicine, used in studies to compare against the active drug and see what real effects the drug has.

How long will I take the study drug?

You would take the study drug (relugolix or placebo) every day for about six months.

Will this study affect my usual doctor’s care?

No, joining a study like this should not affect your regular medical care. Your doctors will work together.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.